Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 32.28 USD 0.5% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Immunocore Holdings PLC
Stock-Based Compensation

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Immunocore Holdings PLC
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Immunocore Holdings PLC
NASDAQ:IMCR
Stock-Based Compensation
ÂŁ32.5m
CAGR 3-Years
58%
CAGR 5-Years
117%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Stock-Based Compensation
ÂŁ24.4m
CAGR 3-Years
127%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Stock-Based Compensation
$11.2m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Immunocore Holdings PLC
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.

IMCR Intrinsic Value
118.25 USD
Undervaluation 73%
Intrinsic Value
Price

See Also

What is Immunocore Holdings PLC's Stock-Based Compensation?
Stock-Based Compensation
32.5m GBP

Based on the financial report for Dec 31, 2023, Immunocore Holdings PLC's Stock-Based Compensation amounts to 32.5m GBP.

What is Immunocore Holdings PLC's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
117%

Over the last year, the Stock-Based Compensation growth was -1%. The average annual Stock-Based Compensation growth rates for Immunocore Holdings PLC have been 58% over the past three years , 117% over the past five years .

Back to Top